Biomea Fusion (BMEA) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Spero Therapeutics (SPRO) over the past year, losing 42.5% versus a loss of 50.2%. Over five years, BMEA leads with a -92.1% price change compared with -93.5% for SPRO. Spero Therapeutics is the larger company by market cap ($64.1 million vs $62.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | SPRO |
|---|---|---|
| Share price | $0.8689 | $1.10 |
| Market cap | $62.82M | $64.06M |
| 1-day change | +3.89% | -2.65% |
| YTD return | -29.93% | -52.79% |
| 1-year return | -42.46% | -50.23% |
| 5-year return | -92.09% | -93.48% |
| P/E ratio (TTM) | — | 7.86 |
| EPS (TTM) | $-0.29 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | $-61.80M | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $2.24 | $3.08 |
| 52-week low | $0.7995 | $1.08 |
| Distance from 52-week high | -61.16% | -64.29% |
| Analyst consensus | buy | none |
| Avg. price target upside | +705.62% | +354.55% |
| Average volume | 1.93M | 962.41K |
| Shares outstanding | 72.30M | 58.23M |
| Employees | 37 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
BMEA vs SPRO FAQ
Which is bigger, Biomea Fusion or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $64.06M compared with $62.82M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or SPRO?
BMEA returned -42.46% over the past 12 months, compared with -50.23% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.